FGFR as potential target in the treatment of squamous non small cell lung cancer

Highlights • Squamous lung cancers have been regarded as tumors without targetable molecular alterations. • FGF/FGFR pathway deregulation is increasingly recognized across different tumors. • FGF/FGFR pathway is one of the most promising druggable target in squamous lung cancers. • FGFR amplificatio...

Full description

Saved in:
Bibliographic Details
Published inCancer treatment reviews Vol. 41; no. 6; pp. 527 - 539
Main Authors Tiseo, Marcello, Gelsomino, Francesco, Alfieri, Roberta, Cavazzoni, Andrea, Bozzetti, Cecilia, De Giorgi, Anna Maria, Petronini, Pier Giorgio, Ardizzoni, Andrea
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 01.06.2015
Subjects
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Squamous Cell - drug therapy
FGF
FGFR
Gene Amplification
Gene Fusion
Hematology, Oncology and Palliative Medicine
Humans
Lung Neoplasms - drug therapy
Mutation
NSCLC
Protein Kinase Inhibitors - therapeutic use
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Receptor, Epidermal Growth Factor - chemistry
Receptor, Epidermal Growth Factor - genetics
Receptor, Epidermal Growth Factor - physiology
Signal Transduction
Squamous cell carcinoma
TKI
Squamous cell carcinoma
TKI
NSCLC
FGF
FGFR
Online AccessGet full text

Cover

More Information
Summary:Highlights • Squamous lung cancers have been regarded as tumors without targetable molecular alterations. • FGF/FGFR pathway deregulation is increasingly recognized across different tumors. • FGF/FGFR pathway is one of the most promising druggable target in squamous lung cancers. • FGFR amplifications, mutations, translocations are the most frequent mechanisms of activation. • mAbs, ligand traps, TKIs directed versus FGF/FGFR are in development in lung tumor.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0305-7372
1532-1967
DOI:10.1016/j.ctrv.2015.04.011